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Progesterone, in various forms, has 
been the sole pharmacologic 
weapon against preterm labor 
supported by randomized controlled 
trials since the groundbreaking work 
of da Fonseca1 and Meis2 in the early 
2000s.  
 
Progesterone is indicated in 
preventing recurrent preterm labor 
and preterm delivery in the setting of 
a history preterm delivery due to 
cervical insufficiency or unexplained 
preterm delivery. This is what the 
evidence supports. However, many 
investigators are trying to expand the 
indications for the use of 
progesterone. These include using 
progesterone in twin pregnancies 
and in the setting of a short cervix. 
To date, no investigator has 
published data supporting the use of 
of progesterone in multiple 
gestations. However, there is good 
evidence to support the use of 
progesterone in women with a short 
cervix.  
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This was recently reaffirmed by work 
done by Hassan, et al as part of the 
PREGNANT trial.3 Furthermore, a 
decision and cost analysis by Cahill, 
et al showed that universal screening 
for a short cervix and treatment with 
vaginal progesterone was cost 
effective.4 However, the most recent 
ACOG guidelines only support the 
use of progesterone in women with 
an incidentally found short cervix.5 
 
Nightly vaginal suppositories and 
weekly injections were the first forms 
of progesterone proved to be 
effective in preventing preterm labor. 
The effectiveness of nightly vaginal 
gel was then demonstrated by 
O’Brien6. These options are all 
relatively affordable. Suppositories 
and gel are only available in branded 
forms under the names Endometrin, 
Crinone and Prochieve. Until 
recently the intramuscular injection 
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K-V Pharmaceutical, through its 
wholly owned subsidiary, Ther-Rx 
Corporation, recently brought 
Makena to the market. This is an 
FDA-approved once weekly injection 
of 17-alpha-OH-progesterone 
caproate intended for the prevention 
of preterm labor. Although having 
this available in retail pharmacies 
would make prescribing 
progesterone for patients easier in 
some circumstances, the cost was 
widely felt to be prohibitively 
expensive for the vast majority of 
patients - $1500 per injection. 
Therefore, the total retail price of 
prescribing Makena for weeks 16 
through 36 in a pregnancy would be 
$31,500. Makena was met with 
much resistance from the OBGYN 
community for this reason. The 
situation was particularly frightening 
because the manufacturer of 
Makena had sent cease and desist 
orders to compounding pharmacies 
that made progesterone injections. 
Thus, the only option for injectable 
progesterone would have been 
inaccessible to most patients due to 
cost. 
 
After much lobbying from the 
American College of Obstetricians 
and Gynecologists (ACOG), the 
Society for Maternal-Fetal Medicine, 
and other societies, the FDA made 
an unprecedented statement on 
March 30th of this year. They 
announced that the FDA “does not 
intend to take enforcement action 
against pharmacies that compound 
hydroxyprogesterone caproate.”7 K-V 
Pharmaceutical announced on April 
1st that it would lower the price of 
Makena from $1500 to $690 per 
dose. Presumably, this was in 
response to the backlash that the 
company received from the OBGYN 
community, the FDA and the press.8 
However, according to ACOG, this 
price reduction remains a “woefully 
inadequate response.”9 
 
Fortunately, there are other forms of 
progesterone available, at very 
reasonable prices, for preterm labor 
prophylaxis. Table 1 is a guide to the 
various forms of progesterone 
currently available. The total cost is 
based on a 21-week course of 
treatment, starting at 16 weeks 
gestation and continuing until 36 
completed weeks. Several factors 
must be considered when choosing 
a product for a patient. These 
include route of administration, 
patient preference, local availability 
and cost.   
 
It is hoped that the information 
provided in this review will be helpful 
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Table 1: Various forms of progesterone and associated costs for 21-week course of treatment 
 
Formulation Dosing Retail price Price per dose Total cost for 21 
weeks of 
treatment 
Endometrin 100 mg vaginal 
insert nightly 
$157 per 21 
insert pack 
$7.48 $1,099.56 
Prometrium 100 mg vaginal 
capsule nightly 
$69 per 30 
capsules 
$2.30 $338.10 
Crinone 90 mg vaginal 
gel nightly 
$170 per 10 
tubes 
$17.00 $2,499.00 
Prochieve 90 mg vaginal 
gel nightly 
$221 per 18 
tubes 
$12.28 $1,805.16 













$136 per 10 
injections 
$13.60 $285.60 
Retail pricing according to www.drugstore.com 
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